A once-daily pill for ulcerative colitis has delivered strong results in a clinical trial, easing symptoms even in patients ...
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...
InvestorsHub on MSN
Abivax Shares Surge After Strong Phase 3 Results in Ulcerative Colitis Study
Abivax SA ADR (NASDAQ:ABVX) shares climbed 7.7% in premarket trading Monday after the clinical-stage biotechnology company ...
The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...
DEAR DR. ROACH: You recently wrote about colitis, aka inflammation of the colon. Could you please explain how to treat and prevent it? -- M.C. ANSWER: “Colitis” does mean inflammation of the colon, ...
Eli Lilly's four-year LUCENT-3 study shows Omvoh maintained high remission rates and a consistent safety profile in ...
You were just diagnosed with ulcerative colitis. Now what? Here, gastroenterologists share the 7 questions to ask your doctor ...
The TNF-alpha inhibitor is indicated to treat children weighing at least 15 kg living with moderately to severely active ...
The U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen of Tremfya (guselkumab) for the ...
New data from Eli Lilly and Company (NYSE: LLY) showed Omvoh (mirikizumab-mrkz) is the first and only interleukin-23p19 ...
FDA approves Johnson & Johnson's Simponi for children with moderate to severe ulcerative colitis, supported by positive Phase ...
Johnson & Johnson (NYSE: JNJ) today announced additional Week 12 results from the Phase 2b ANTHEM-UC study of icotrokinra, a first-in-class investigational targeted oral peptide that selectively ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback